Manufacturer of Controlled Substances; Notice of Application, 46233 [E9-21523]

Download as PDF 46233 Federal Register / Vol. 74, No. 172 / Tuesday, September 8, 2009 / Notices Springfield, Virginia 22152; and must be filed no later than November 9, 2009. Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Manufacturer of Controlled Substances; Notice of Registration By Notice dated April 17, 2009, and published in the Federal Register on April 29, 2009, (74 FR 19598), Cambrex Charles City, Inc., 1205 11th Street, Charles City, Iowa 50616, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule II: DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Dated: August 21, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–21525 Filed 9–4–09; 8:45 am] DEPARTMENT OF JUSTICE By Notice dated April 17, 2009, and published in the Federal Register on April 29, 2009, (74 FR 19597), Rhodes Technologies, 498 Washington Street, Coventry, Rhode Island 02816, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Drug Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on July 7, 2009, National Center for Natural Products Research—NIDA MProject, University of Mississippi, 135 Coy Waller Lab Complex, University, Mississippi 38677, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I: Amphetamine (1100) .................... Methamphetamine (1105) ............ Lisdexamfetamine (1205) ............. Methylphenidate (1724) ................ Phenylacetone (8501) .................. Codeine (9050) ............................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Dextropropoxyphene, bulk (nondosage forms) (9273). Morphine (9300) ........................... Thebaine (9333) ........................... Sufentanil (9740) .......................... Fentanyl (9801) ............................ II II II II II II II II II II II II II Drug Tetrahydrocannabinols (7370) ..... Methylphenidate (1724) ................ Codeine (9050) ............................. Dihydrocodeine (9120) ................. Oxycodone (9143) ........................ Hydromorphone (9150) ................ Hydrocodone (9193) ..................... Oripavine (9330) ........................... Thebaine (9333) ........................... Oxymorphone (9652) ................... Noroxymorphone (9668) .............. Fentanyl (9801) ............................ Schedule I II II II II II II II II II II II Dated: August 21, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–21528 Filed 9–4–09; 8:45 am] I I The company plans to cultivate marihuana for the National Institute on Drug Abuse for research approved by the Department of Health and Human Services. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than November 9, 2009. Dated: August 28, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–21523 Filed 9–4–09; 8:45 am] BILLING CODE 4410–09–P 17:32 Sep 04, 2009 Dated: August 21, 2009. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E9–21533 Filed 9–4–09; 8:45 am] BILLING CODE 4410–09–P Schedule Marihuana (7360) ......................... Tetrahydrocannabinols (7370) ..... VerDate Nov<24>2008 The company plans to manufacture the listed controlled substances in bulk for sale to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cambrex Charles City, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Cambrex Charles City, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. The company plans to manufacture the listed controlled substances in bulk for conversion and sale to dosage form manufacturers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Rhodes Technologies to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Rhodes Technologies to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. BILLING CODE 4410–09–P Drug jlentini on DSKJ8SOYB1PROD with NOTICES Schedule Jkt 217001 PO 00000 Frm 00154 Fmt 4703 Sfmt 4703 E:\FR\FM\08SEN1.SGM 08SEN1

Agencies

[Federal Register Volume 74, Number 172 (Tuesday, September 8, 2009)]
[Notices]
[Page 46233]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-21523]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on July 7, 2009, National Center 
for Natural Products Research--NIDA MProject, University of 
Mississippi, 135 Coy Waller Lab Complex, University, Mississippi 38677, 
made application by renewal to the Drug Enforcement Administration 
(DEA) to be registered as a bulk manufacturer of the basic classes of 
controlled substances listed in schedule I:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Marihuana (7360)...........................  I
Tetrahydrocannabinols (7370)...............  I
------------------------------------------------------------------------

    The company plans to cultivate marihuana for the National Institute 
on Drug Abuse for research approved by the Department of Health and 
Human Services.
    Any other such applicant, and any person who is presently 
registered with DEA to manufacture such substances, may file comments 
or objections to the issuance of the proposed registration pursuant to 
21 CFR 1301.33(a).
    Any such written comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than November 9, 2009.

    Dated: August 28, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E9-21523 Filed 9-4-09; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.